



Thursday, May 14, 2015
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 125

Board Members Present:

Tony Dalpiaz, PharmD.
Michael Symond, M.D.
Keith Tolman, M.D.
Mr. Kumar Shah

Jennifer Brinton, MD
Jay Aldus, DDS
Susan Siegfroid, M.D

Board Members Excused:

Kyle Jones, M.D.
George Hamblin, PharmD

Mark Balk, PharmD.

Dept. of Health/Div. of Health Care Financing Staff Present:

Robyn Seely, Pharm.D
Trevor Smith C.Ph.T.
Heather Santacruz, R.N .

Lisa Hunt, RPh
Merelynn Berrett, R.N.
Alyssa Pitts, R.N.

Other Individuals Present:

Joanita Lake, UofU

Meeting conducted by: Tony Dalpiaz, Pharm.D.

- 1. Welcome** – Tony Dalpiaz opened the meeting.
- 2. Housekeeping** – Robyn Seely welcomed everyone to the meeting and reminded everyone to sign in. She said that there are two petitions today for the board to review following the public portion of the meeting.
- 3. P&T Committee report** – Lisa Hunt said that the next P&T committee will discuss agents to treat angina and hepatitis C combination agents. She also said that there are two new committee members including Dr. Keith Tolman and Dr. Clinton Sheffield.
- 4. Approval of prior meeting minutes** – Keith Tolman made a motion to approve the February meeting minutes. Kumar Shah seconded the motion. All in favor.
- 5. Quantity Limits on Skeletal-muscular relaxants** – Robyn Seely said that she wants to increase the quantity limits on skeletal muscular relaxants to match the FDA guidelines.
- 6. Grastek, Ragwitek and Oralair** – Joanita Lake from the University of Utah DRRC

presented drug information including disease symptoms, studies, side effects, indications and other information about Grastek, Ragwitek and Oralair products. Data was also presented about the utilization of the drugs in the Utah Medicaid population.

7. Public Comment

- a. No Public Comment.

8. Board Discussion

- a. Jennifer Brinton said that it is difficult to ensure patient compliance with these medications, since they take them prior to the allergy season, when there is usually no physical symptoms. She asked if there is a way to include an educational aspect to the PA form.
- b. Jennifer Brinton said that the sublingual tablets would be more beneficial for children or those who have fear of needles.
- c. Mike Symond said that those who have allergies serious enough to use allergy shots or the products under review today would be more likely to be compliant with the dosing regimen since the allergies are so severe.
- d. Joanita Lake said that looking at utilization data from last year, many patients have discontinued the drug prematurely.
- e. Susan Siegfried said that the advantage of allergy shots is that the patient needs to keep the appointment with the doctor to receive the medication. With the sublingual formulations, the patient has to be compliant on their own.
- f. Lisa Hunt explained that the criteria has specific dates when the medication must be started comes from FDA guidelines and the dates when the different allergy seasons occur in Utah.
- g. Jennifer Brinton said that the new allergy immunotherapy is a game changer for pediatric patients. It encourages a healthier lifestyle as they are able to participate in outdoor activities during their childhood.
- h. Mike Symond said it is important to trust allergists and pharmacists will provide counseling and education.
- i. Tony Dalpiaz asked about the authorization period as they are inconsistent in the proposed criteria.
- j. Jennifer Brinton made a motion that Oralair should be started 16 weeks before the allergy season. Mike Symond seconded the motion. All in favor.
- k. Jennifer Brinton made a motion to keep Grastek and Ragwitek the same as they are currently. Mike Symond seconded the motion. All in favor.
- l. Mike Symond made a motion the Ragwitek should have a three year authorization like to be consistent. Kumar Shah seconded the motion. All in favor.

9. Meeting Adjourned - Jennifer Brinton made a motion to close the public portion of the meeting. Kumar Shah seconded the motion. All in favor.

10. Two petitions were reviewed.

The next DUR Board meeting is scheduled for Thursday, June 11th. Tentative schedule is to discuss androgen products, Aveed, Natesto and Volgelxo.

Minutes prepared by Trevor Smith.

Recording available upon request, send email to medicaidpharmacy@utah.gov